Watch video on www.urotoday.com
Fabio Almeida, MD // Phoenix Molecular Imaging – Phoenix Insight Imaging/CDI
Over the last few years, we have seen tremendous activity in the area of molecular imaging for prostate cancer. Just about every day we have colleagues asking about the various PET/CT imaging tests – what is available? How do they compare? What are the parameters for successful imaging?
We are proud to be contributing to this body of knowledge. Our work regarding C11-Acetate PET/CT imaging in the recurrent PCa setting with relationship to PSA kinetics has been recently published. This represents the largest single-site evaluation of a molecular imaging agent. A link to the publication and brief overview PET/CT imaging for Prostate Cancer follow for your review. We hope you find this information useful.
Read or download the report from here
Dr. Thomas Hope, Assistant Professor of Radiology at UCSF presented at the San Jose Prostate Cancer Support Group on the topic of Prostate-specific membrane antigen (PSMA) imaging and treatment of patients with prostate cancer.
Read or download his presentation from here
Article by Fabio D Almeida1, Chi-Kwan Yen1, Mark C Scholz2, Richard Y Lam2, Jeffrey Turner2, Larry L Bans3, Robert Lipson3
Performance characteristics and relationship of PSA value/kinetics on carbon-11 acetate PET/CT imaging in biochemical relapse of prostate cancer.
Read or download the report from here
The following information was obtained from several sources including University of British Columbia, The Vancouver Sun and others.
John Oliffe, head of Men’s Health Research and a professor in the School of Nursing has developed a new interactive website called “If I Were Tom” (ifiweretom.ubc.ca)
This website has been five years in the making. The idea started in 2012, when researchers surveyed health specialists and patients to find out what they most want to discuss when dealing with prostate cancer. Another two years of video interviews followed, using a $400,000.00 grant from the Canadian Institutes of Health Research. There are 30 videos on the website, with more ready to be swapped in order to keep everything fresh.
The website is interactive, so the viewer can predict what Tom (actor Gary Johnston plays the role) will do at each step along the way from diagnosis to recovery. “Will I have to wear these stupid underpants that make you look like you’re walking around with a load in your pants?” Tom asks himself when worrying about potential side effects of surgery.
“We’ve found with guys that if a character resonates with them they’re drawn into the content in a more interactive way. You look at the video and put in what you would do next. You might be plotting what Tom’s doing, but chances are you’re plotting what you did or think you’d do,” said Oliffe.
Like a support group session, but on line. There is already a mountain of information available about prostate cancer, concedes Oliffe, and the website isn’t trying to duplicate that. Instead, each topic area includes a video from specialists including urologist, oncologist and psychologist and also includes men with prostate cancer talking about their real experiences. It also includes no-holds-barred discussion on sexual problems and hormonal changes.
We’re really trying to create a resource that was similar for all those guys who don’t want to go to a group because of privacy issues or who can’t get there because of transportation or work commitments etc.
You can’t have too much information. There are different types of prostate cancer – slow growing or aggressive – there are various treatment options to treat prostate cancer including surgery to remove the prostate gland surgically.
Another option may be radiation therapy, anti-hormone treatment known as androgen deprivation therapy or doing something referred to as active-surveillance (where you and your PSA etc. are watched very closely and if and when things change then treatment options are offered). Age and other health problems will also play into each man’s choice of treatment.
“They might be disappointed with the outcome, but if you go in knowing the potential side effects and having thoughtfully considered those, taking time rather than being rushed…you’re less likely to make a decision quickly about a treatment you might regret.”
Research continues. Oliffe’s team is collecting more data through the website with surveys. I believe at the present time they are asking about a persons exercise regime.
The U.S. Food and Drug Administration today granted accelerated approval to a treatment for patients whose cancers have a specific genetic feature (biomarker). This is the first time the agency has approved a cancer treatment based on a common biomarker rather than the location in the body where the tumor originated.
Read more on fda.gov
Following a prostate cancer diagnosis, patients are faced with a multitude of care options, the advisability of which is influenced by patient factors and by cancer severity or aggressiveness. The ability to categorize patients based on cancer aggressiveness is invaluable for facilitating care decisions.
Accordingly, these guidelines for the management of localized prostate cancer are structured first, to provide a clinical framework stratified by cancer severity (or risk group) to facilitate care decisions and second, to guide the specifics of implementing the selected management options.
In Scope: active surveillance, observation/watchful waiting, prostatectomy, radiotherapy, cryosurgery, high intensity focused ultrasound (HIFU) and focal therapy.
Out of Scope: Secondary or salvage treatment for localized prostate cancer that persists or recurs after primary definitive intervention, and primary treatment of locally advanced/metastatic disease.
Here is the latest issue of Prostate Cancer Communication. It is a publication from PAACT (Patient Advocates for Advanced Cancer Treatments). There are some good articles that may be of interest to you.
From PBS interview with Dr .Elisabeth Rosenthal. 6 Questions to ask your doctor.
A newly published study in the journal Urology (the “Gold Journal”) has suggested that — at least for patients with a PSA level between 4 and 10 ng/ml — PSA density may be better than PSA level in the determination of which of these patients need to go on to have a biopsy.
- PSA density was a much more accurate predictor of risk than PSA alone for all men with a PSA level of 4 ng/ml or higher.
- Among men with a PSA level of < 4 ng/ml, PSA density was no better than PSA at predicting actual prostate cancer (of any type or of clinical significance).